CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 24 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-10 | Gallagher Cam Director | Grant or award | +7,595 | 403,001 | ||
| 2022-02-10 | Gallagher Cam Director | Grant or award · Stock Option (Right to Buy) | +19,245 | 19,245 | ||
| 2022-02-10 | SUN ANTHONY Y President & CEO | Grant or award | +50,431 | 1,222,206 | ||
| 2022-02-10 | SUN ANTHONY Y President & CEO | Grant or award · Stock Option (Right to Buy) | +118,319 | 118,319 | ||
| 2022-02-07 | Gallagher Cam Director | Sale | −2,290 | $52.77 | $121K | 394,913 |
| 2022-02-07 | Gallagher Cam Director | Sale | −6,460 | $53.51 | $346K | 388,453 |
| 2022-02-07 | Gallagher Cam Director | Sale | −1,250 | $54.35 | $68K | 387,203 |
| 2022-02-02 | SUN ANTHONY Y President & CEO | Sale | −8,128 | $57.87 | $470K | 1,174,118 |
| 2022-02-02 | SUN ANTHONY Y President & CEO | Sale | −2,343 | $58.29 | $137K | 1,171,775 |
| 2022-02-01 | SUN ANTHONY Y President & CEO | Sale | −4,124 | $56.81 | $234K | 1,188,593 |
| 2022-02-01 | SUN ANTHONY Y President & CEO | Sale | −3,419 | $57.63 | $197K | 1,185,174 |
| 2022-02-01 | SUN ANTHONY Y President & CEO | Sale | −2,828 | $58.59 | $166K | 1,182,346 |
| 2022-02-01 | SUN ANTHONY Y President & CEO | Sale | −100 | $59.31 | $6K | 1,182,246 |
| 2022-01-20 | Voliotis Dimitris SVP, Clinical Development | Exercise or conversion | +10,000 | $18.00 | $180K | 16,250 |
| 2022-01-20 | Voliotis Dimitris SVP, Clinical Development | Sale | −8,343 | $60.52 | $505K | 7,907 |
| 2022-01-20 | Voliotis Dimitris SVP, Clinical Development | Sale | −1,657 | $61.21 | $101K | 6,250 |
| 2022-01-20 | Voliotis Dimitris SVP, Clinical Development | Exercise or conversion · Stock Option | −10,000 | 124,949 | ||
| 2022-01-20 | Bunker Kevin D. Chief Operating Officer | Sale | −2,753 | $59.17 | $163K | 187,247 |
| 2022-01-20 | Bunker Kevin D. Chief Operating Officer | Sale | −6,537 | $60.20 | $394K | 180,710 |
| 2022-01-20 | Bunker Kevin D. Chief Operating Officer | Sale | −710 | $61.29 | $44K | 180,000 |
Page 12 of 28 · 545 trades